A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Phase 3
408
about 4.1 years
12+
49 sites in AL, AR, AZ +24
About this study
Researchers are testing whether etavopivat reduces the number of vaso-occlusive crises (sickle cell pain crises) caused by blood vessel blockages in adults and adolescents with sickle cell disease. The trial will also evaluate how well etavopivat can reduce organ damage, improve exercise tolerance, and decrease fatigue in people with sickle cell disease. Participants will either receive etavopivat or a placebo. Which treatment they get is decided randomly. Etavopivat is a new medicine being tested in other studies as well.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Etavopivat
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Change in distance travelled during the 6-minute walking test (6MWT), Change in standardised T-score on the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Scale, Participants achieving the threshold for clinically meaningful change (yes/no) in 6MWT, Participants achieving the threshold for clinically meaningful change (yes/no) in PROMIS fatigue scale 7a